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a  b  s  t  r  a  c  t
Human  papillomavirus  (HPV)  vaccines  confer  protection  against  the  oncogenic  genotypes  HPV16  and
HPV18  through  the  generation  of  type-speciﬁc  neutralizing  antibodies  raised  against  the constituent
virus-like  particles  (VLP)  based  upon  the  major  capsid  proteins  (L1) of  these  genotypes.  The  vaccines  also
confer  a degree  of  cross-protection  against  some  genetically  related  types  from  the  Alpha-9  (HPV16-like:
HPV31,  HPV33,  HPV35,  HPV52,  HPV58)  and Alpha-7  (HPV18-like:  HPV39,  HPV45,  HPV59,  HPV68)  species
groups.  The  mechanism  of  cross-protection  is  unclear  but  may  involve  antibodies  capable  of recognizing
shared  inter-genotype  epitopes.  The  relationship(s)  between  the  genetic  and  antigenic  diversity  of  the
L1  protein,  particularly  for  non-vaccine  genotypes,  is  poorly  understood.
We  carried  out  a comprehensive  evaluation  of the immunogenicity  of  L1 VLP derived  from  geno-
types  within  the Alpha-7  and  Alpha-9  species  groups  in  New  Zealand  White  rabbits  and  used  L1L2
pseudoviruses  as  the  target  antigens  in neutralization  assays.
The majority  antibody  response  against  L1 VLP  was  type-speciﬁc,  as expected,  but several  instances  of
robust  cross-neutralization  were  nevertheless  observed  including  between  HPV33  and  HPV58  within  the
Alpha-9  species  and  between  HPV39,  HPV59  and  HPV68  in the  Alpha-7  species.  Immunization  with  an
experimental  tetravalent  preparation  comprising  VLP based  upon  HPV16,  HPV18,  HPV39  and  HPV58 was
capable  of generating  neutralizing  antibodies  against  all the  Alpha-7  and  Alpha-9  genotypes.  Competition
of  HPV31  and  HPV33  cross-neutralizing  antibodies  in the  tetravalent  sera  conﬁrmed  that  these  antibod-
ies  originated  from  HPV16  and  HPV58  VLP,  respectively,  and  suggested  that  they  represent  minority
speciﬁcities  within  the  antibody  repertoire  generated  by  the  immunizing  antigen.  These data  improve
our  understanding  of the  antigenic  diversity  of the  L1 protein  per  se and may  inform  the  rational  design
of  a  next  generation  vaccine  formulation  based  upon  empirical  data.
ht  © 2Crown  Copyrig
. Introduction
Human papillomavirus (HPV) vaccines, Cervarix® and
ardasil®, comprise virus-like particles (VLP) based upon the
ajor capsid protein (L1) of HPV16 and HPV18 and are highly
fﬁcacious at preventing persistent infection and more pro-
ressive disease associated with these two high risk genotypes
n clinical trials [1]. Gardasil® also contains VLP representing
PV6 and HPV11, the principal genotypes associated with genital
arts. HPV16 and HPV18 account for ca. 70% of cervical cancers
orldwide [2,3] and recent epidemiological data for Australia
∗ Corresponding author at: Virus Reference Department, Public Health England,
1  Colindale Avenue, London NW9  5EQ, UK. Tel.: +44 0208327 6169.
E-mail  address: simon.beddows@phe.gov.uk (S. Beddows).
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icenses/by-nc-nd/3.0/).014  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
[4], the USA [5] and the UK [6,7] demonstrate reductions in the
prevalence of these two genotypes following the introduction
of national HPV vaccination programs. Neutralizing antibodies
against HPV16 and HPV18 can be detected in the serum and
cervicovaginal secretions of vaccinees [8–10] and passive transfer
of immune sera, puriﬁed immunoglobulin (IgG) and monoclonal
antibodies (MAbs) can protect animals against papillomavirus
challenge [11–13]. These observations have led to the reasonable
assumption that vaccine-induced, type-speciﬁc protection is
mediated by neutralizing antibodies [1,14].
Cross-protection has also been demonstrated against some
genotypes within the Alpha-papillomavirus species groups, Alpha-
9 (HPV16-like: HPV31, HPV33, HPV35, HPV52, HPV58) and Alpha-7
(HPV18-like: HPV39, HPV45, HPV59, HPV68) [1,15,16] and coin-
cides with the detection of cross-neutralizing antibodies in the
serum and cervicovaginal secretions of vaccinees [10,17–20]. Such
access article under the CC BY-NC-ND license (http://creativecommons.org/
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heatmap representation of log10 titers (range 1.0–6.0 log10) was
employed with titers below the assay threshold of 20 being cen-
sored with a value of 10 (1.0 log10). The phylogenetic relationshipS.L. Bissett et al. / Vac
ntibodies may  be effectors, or their detection may  have utility as
 correlate or surrogate of vaccine-induced cross-protection [21].
The  development of potential next generation vaccines to
mprove the breadth of genotype coverage [1,22] is based
pon two approaches: improving the immunogenicity of a con-
erved region of the minor capsid protein (L2) to generate
roadly neutralizing antibodies [23], and using a multiva-
ent L1 VLP-based vaccine that induces type-speciﬁc antibodies
gainst a wider array of HPV genotypes (HPV6, HPV11, HPV16,
PV18, HPV31, HPV33, HPV45, HPV52, HPV58; V503, Merck
esearch Laboratories). The latter approach is the most advanced
nd early clinical trial data show promising immunogenicity and
fﬁcacy proﬁles [24], whereas L2-based candidate vaccines are
urrently in pre-clinical development [23]. Reduced dosing sched-
les for the current HPV vaccines are also being investigated
ith data suggesting non-inferiority of type-speciﬁc antibody
esponses, although there is an impact on the development of cross-
eutralizing antibodies [10,25–27].
Early pre-clinical immunogenicity [28–30] and MAb  reactivity
17] data suggest a degree of inter-genotype antigenic similar-
ty within the Alpha-7 and Alpha-9 species groups. The extent of
his antibody cross-reactivity is unclear as only a limited num-
er of immunogens and target antigens have been used. Some
f these data have been generated using L1-based targets [28],
ather than pseudovirus targets bearing both the L1 and L2 pro-
eins, with both proteins being necessary for efﬁcient infectivity
nd the appropriate presentation of L1 conformational epitopes
23,31,32].
We carried out a comprehensive pre-clinical evaluation of the
mmunogenicity of L1 VLP derived from multiple HPV genotypes
ithin the Alpha-7 and Alpha-9 species groups and used L1L2
seudoviruses, representing these same genotypes, as the target
ntigens in neutralization assays. Such data should improve our
nderstanding of the antigenic diversity of the L1 protein per se
nd may  inform the design of a next generation vaccine formula-
ion that encompasses a limited number of antigens based upon
mpirical data.
.  Materials and methods
.1.  L1 VLP immunogens
Cervarix® was obtained through the National Vaccine Evalua-
ion Consortium, UK.
L1  VLP representing Alpha-7 and Alpha-9 HPV genotypes and
ontrol Bovine Papillomavirus (BPV) were expressed using the
ac-to-Bac® Baculovirus System (Life Technologies), as previously
escribed [33,34], wherein the L1 genes shared 100% amino acid
equence identity with the L1 genes of the pseudovirus clones [20]
sed for the neutralization assay (see Section 2.3).
.2. Immunization protocols
Five  week old female BALB/c mice were immunized with saline
naïve) or 1/10th (2 g each HPV16 and HPV18 VLP) the human
ose equivalent of Cervarix® [35] by the intramuscular (IM) or sub-
utaneous (SC) routes. Two schedules were investigated whereby
mmunizations were carried out at week (W)  0, W3  and W7  or at
0,  W4 and W12.
Eight  to ten week old female New Zealand White (NZW) rabbits
ere immunized subcutaneously with saline (naïve) or 1/4th
5 g each HPV16 and HPV18 VLP) the human dose equivalent of
ervarix® at W0,  W4 and W12.
Eight to ten week old female NZW rabbits were immunized sub-
utaneously with 5 g each of the indicated in house L1 VLP (or2 (2014) 6548–6555 6549
5  g each of HPV16, HPV18, HPV39 and HPV58 for the tetrava-
lent preparation). VLP were absorbed onto 3% alhydrogel (250:1
(v/v), Superfos Biosector) for 1–2 h at room temperature under
gentle rotation. For the ﬁnal preparation of the rabbit inocu-
lum, the VLP-alhydrogel mix  was  diluted in sodium phosphate
buffer pH 6.5 (ﬁnal concentration 2.7 mM NaH2PO4 and 3.3 mM
Na2HPO4) with 150 mM  NaCl, alhydrogel (250 g/mL Al3+), Sigma
Adjuvant System (25 g/mL monophosphoryl lipid), and incu-
bated with gentle rotation at room temperature for a minimum
of 15 min. Rabbits received additional immunizations at W4 and
W12.
In all cases, serum samples were collected prior to the ﬁrst
immunization (pre-immunization) and two weeks following both
the second and third doses.
All  animal husbandry and regulated procedures were carried out
in strict accordance with UK Home Ofﬁce guidelines and governed
by the Animals (Scientiﬁc Procedures) Act 1986 which complies
with the EC Directive 2010/63/EU and performed under licences
PPL 80/2537 and PPL 70/6562-3 granted only after review of all the
procedures in the licence by the local Animal Welfare and Ethical
Review Bodies.
2.3.  Neutralization assay
L1L2  pseudoviruses representing Alpha-7 and Alpha-9 HPV
genotypes and BPV, and carrying a luciferase reporter, were
expressed from transiently transfected 293TT cells, puriﬁed and
characterized as previously described [20,36]. The equivalent of
a Tissue Culture Infectious Dose 50% (TCID50) was estimated
using the Spearman-Karber equation and a standardized input
of 300 TCID50 was used for all pseudoviruses. Serum samples
were serially diluted and the 80% reciprocal neutralization titer
estimated by interpolation. Heparin (H-4784; Sigma–Aldrich, UK)
was included as a positive inhibitor control and as an indi-
cator of inter-assay reproducibility. The median (Inter-quartile
range, IQR) inhibitory concentrations (g/mL) were as fol-
lows: HPV16 11.9 (9.5–22.3; n = 7), HPV31 5.1 (3.3–8.1; 6),
HPV33 13.1 (7.4–19.4; 6), HPV35 3.1 (2.9–4.9; 6), HPV52 25.2
(13.6–31.9; 6), HPV58 8.2 (3.6–19.4; 6), HPV18 3.9 (3.4–5.0;
n = 6) HPV39 5.8 (4.0–7.2; 5), HPV45 3.7 (3.5–3.9; 6), HPV59 13.6
(11.7–16.3; 6), HPV68 7.0 (6.5–12.1; 6) and BPV 73.5 (59.1–75.9;
5).
2.4. Competition of neutralizing antibodies using L1 VLP
Serial  dilutions of selected ﬁnal bleed rabbit sera were pre-
incubated for 1hr at room temperature with 2 g of L1 VLP (HPV16,
HPV31, HPV33 or HPV58), followed by addition of 300 TCID50 of
L1L2 pseudoviruses representing the same HPV genotypes for 1 h at
room temperature, before being transferred to 293TT cells for 72 h
at 37 ◦C. The 80% reciprocal neutralization titers were estimated by
interpolation.
2.5. Data analyses
For  the comparison of inter-genotype neutralization data abetween L1 amino acid sequences (neighbor-joining [NJ] tree)
and inter-genotype distance matrices (n = 500 bootstrap repli-
cates; heatmap range 0.0–1.0) were created using Mega v4.1
[37].
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Fig. 1. Neutralizing antibody responses following Cervarix® immunization of
mice, rabbits and humans. Box and whisker plot of type-speciﬁc (HPV16),
cross-neutralizing (HPV31) and non-speciﬁc control (BPV) responses following
immunization  of BALB/c mice (3 × 1/10 dose), NZW rabbits (3 × 1/4 dose) and
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were selected based upon their high HPV31 and HPV33 neutralizingumans  (3 × 1 dose; reproduced from [20] for comparison purposes) with indicated
ose of Cervarix® HPV vaccine.
. Results
.1. Immunization of BALB/c mice and NZW rabbits with
ervarix®
As both HPV vaccines consistently generate HPV31 cross-
eutralizing antibodies following immunization, we used this as
 benchmark for selecting an appropriate animal model for our
re-clinical immunization studies. BALB/c mice were immunized
ntra-muscularly with Cervarix® over a 7 week schedule result-
ng in a median HPV16 neutralizing antibody titer of 10,416
IQR 7943–16,862; n = 10) (Fig. 1). Cross-neutralization of HPV31,
owever, was only apparent in one mouse (HPV31 titer of 733)
ith a very high HPV16 neutralizing titer of 543,122. Cervarix®
mmunization of BALB/c mice sub-cutaneously or intra-muscularly
ver a 12 week schedule did not elicit neutralizing antibodies
gainst HPV31 (data not shown). Conversely, immunization of NZW
abbits with Cervarix® over the same 12 week schedule gener-
ted a median HPV16 neutralizing antibody titer of 40,792 (IQR
8,214–57,869; n = 8) accompanied by a median HPV31 titer of 152
IQR 35–346; n = 8). Although differences in dosing levels between
ice and rabbits may  impact on the antibody responses elicited
ere, HPV31 neutralizing antibody titers generated in rabbits were
imilar to the titers found in human vaccinees (Fig. 1) [20], suggest-
ng that NZW rabbits were an appropriate model for examining the
eneration of cross-neutralizing antibodies following immuniza-
ion with L1 VLP.
.2.  Immunization of NZW rabbits with individual Alpha-7 and
lpha-9  L1 VLP
NZW  rabbits were immunized with L1 VLP representing individ-
al HPV genotypes from the Alpha-7 and Alpha-9 species groups
nd the control BPV. As expected, immunization with L1 VLP
nduced predominantly high titer neutralizing antibodies against
he immunizing genotype resulting in a median type-speciﬁc titer
f 100,287 (IQR 64,478–246,691) (Fig. 2). However, there were
everal cases wherein L1 VLP elicited antibodies capable of neutral-
zing pseudoviruses representing other genotypes. Some of these
esponses were weak and sporadic, while some were of a reason-
ble titer and consistent between animals in the same group. For
xample, HPV33 and HPV58 appeared to share common neutraliza-
ion epitopes resulting in a median reciprocal neutralization titer of
53 (IQR 520–3594). Similarly, although of a lesser magnitude, VLP2 (2014) 6548–6555
representing HPV39 and HPV59 also appeared to share common
neutralization epitopes.
A  phylogenetic representation of the amino acid sequences used
for the Alpha-7 and Alpha-9 VLP and pseudovirus L1 proteins
demonstrates the close relationship between certain genotypes
within each of these two  species groups (Fig. 3A). The amino
acid sequences of the surface-exposed loops [38,39] are likely
to contribute to the antigenic similarity and distinction between
HPV genotypes (Fig. 3B). The median intra-species group surface-
exposed loop genetic distances for these Alpha-7 and Alpha-9
L1 sequences were similar at 0.19 (IQR 0.15–0.20) and 0.24
(0.18–0.24), respectively (p = 0.146), and substantially lower than
the median inter-species genetic distance of 0.37 (0.35–0.40;
p < 0.001). Within the Alpha-9 species group, the antigenic simi-
larity between HPV33 and HPV58 is perhaps reﬂected in the low
genetic distance between these genotypes. The apparent antigenic
relationship between HPV39 and HPV59 within the Alpha-7 species
group, however, is not similarly reﬂected by low genetic distances.
There were other sporadic instances of weaker cross-
neutralization, for example between HPV16, HPV31 and HPV33.
Interpretation of these weaker responses, however, has to be
tempered by the observation that three of the thirty-six rabbits
generated weak inter-species responses: two  animals immunized
with HPV31 VLP (one with cross-reactivity against HPV18 and one
against HPV68) and one animal immunized with HPV35 VLP (cross-
reactivity against HPV45, HPV59 and HPV68). Weak intra-species
group responses are intuitively likely to be genuine, but given
the inter-species genetic distances in the surface-exposed loops
(Fig. 3B) weak inter-species responses should be interpreted with
some caution.
Pre-immune sera were negative for neutralizing antibodies
against all Alpha-7 and Alpha-9 HPV pseudoviruses and the control
BPV (data not shown).
3.3.  Immunization with tetravalent immunogen
A tetravalent preparation containing HPV16, HPV18, HPV39 and
HPV58 VLP was used to immunize a group of ﬁve NZW rabbits fol-
lowing the same schedule as that for the individual immunizations
(Fig. 4). All ﬁve rabbits generated high titer neutralizing antibod-
ies against the immunizing genotypes HPV16, HPV18, HPV39 and
HPV58 and the titers were similar to those obtained when used
as individual immunogens with median individual and tetravalent
type-speciﬁc neutralization titers for HPV16 (80,813 vs. 161,025),
HPV18 (21,941 vs. 17,637), HPV39 (86,678 vs. 53,612) and HPV58
(140,129 vs. 105,258) as indicated (Figs. 2 and 4). Conversely, the
breadth of cross-neutralization seen against the Alpha-7 and partic-
ularly the Alpha-9 pseudoviruses was greater than when VLP were
used individually: all ﬁve rabbits generated neutralizing antibodies
against HPV33 and three to four of ﬁve rabbits also generated neu-
tralizing antibodies against HPV31, HPV35, HPV45, HPV52, HPV59
and HPV68. None of the ﬁve rabbits generated antibodies capable of
neutralizing BPV and pre-immune sera were negative for neutraliz-
ing antibodies against all Alpha-7 and Alpha-9 HPV pseudoviruses.
3.4. Speciﬁcity of cross-reactive antibodies
To establish which of the HPV16 and/or HPV58 VLP immuno-
gen(s) were responsible for the generation of the cross-neutralizing
antibody responses against HPV31 and HPV33 we used VLP as com-
peting antigens in neutralization tests (Table 1 and Supplemental
Fig. S1). For this purpose, serum from animals R38, R39 and R40antibody titers.
Supplementary Fig. S1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.vaccine.2014.07.116.
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Immunogen Rab bit 16 31 33 35 52 58 18 39 45 59 68 Log10
R1 5.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
R2 4. 9 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 2. 0
R3 4. 9 1. 0 1. 5 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 3. 0
R4 1.0 5.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.4 1.0 4.0
R5 1.4 5.5 1.4 1.0 1.0 1.0 1.7 1.0 1.0 1.0 1.0 1.0 5.0
R6 1.0 5.5 1.0 1.0 1.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 6.0
R7 1.5 1.0 5.1 1.0 1.6 2.7 1.0 1.0 1.0 1.0 1.0 1.0
R8 1.0 1.0 4.9 1.0 1.0 2.8 1.0 1.0 1.0 1.0 1.0 1.0
R9 1. 0 1. 0 5. 0 1. 0 1. 0 3. 8 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R10 1.0 1.0 1.0 5.9 1.0 1.0 1.0 1.0 1.3 1.7 1.4 1.0
R11 1. 0 1. 0 1. 0 5. 1 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R12 1.0 1.0 1.0 5.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
R13 1. 0 1. 0 1. 0 1. 0 5. 8 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R14 1. 0 1. 0 1. 0 1. 0 5. 9 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R15 1. 0 1. 0 1. 0 1. 0 5. 9 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R16 1. 0 1. 0 3. 7 1. 0 1. 0 5. 8 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R17 1.0 1.0 2.4 1.0 1.0 4.9 1.0 1.0 1.0 1.0 1.0 1.0
R18 1. 0 1. 8 2. 7 1. 0 2. 6 5. 1 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0
R19 1.0 1.0 1.0 1.0 1.0 1.0 4.1 1.0 1.0 1.0 1.0 1.0
R20 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 5. 3 1. 0 1. 0 1. 0 1. 0 1. 0
R21 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 3 1. 0 1. 0 1. 0 1. 0 1. 0
R22 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 8 1. 0 2. 8 1. 6 1. 0
R23 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 9 1. 0 1. 6 1. 3 1. 0
R24 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 5. 2 1. 0 2. 1 1. 6 1. 0
R25 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 3 1. 0 1. 0 1. 0
R26 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 2. 2 1. 0 4. 0 1. 0 1. 0 1. 0
R27 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 2 1. 0 1. 0 1. 0
R28 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 5 1. 4 1. 0 4. 8 1. 3 1. 0
R29 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 2. 0 1. 4 5. 1 1. 0 1. 0
R30 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 7 1. 0 5. 0 1. 0 1. 0
R31 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 8 1. 0
R32 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 8 1. 0
R33 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 9 1. 0
R34 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 5. 8
R35 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 4
R36 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 1. 0 4. 0
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Hig. 2. Heatmap of type-speciﬁc and cross-neutralizing antibody responses again
ndividual VLP. Log10 neutralization titers of sera from NZW rabbits (n = 3) followin
lpha-9 or BPV pseudoviruses. Key indicates log10 heatmap gradient.
Pre-incubation with HPV16 and HPV58 VLP reduced neutral-
zing antibody titers against their respective pseudoviruses by a
edian 427-fold (or 2.6 log10). For the two animals, R38 and R39,
hat had the highest levels of HPV31 neutralizing antibodies (Fig. 4),
ompetition with HPV16 or HPV31 VLP, but not HPV33 or HPV58
LP, reduced neutralizing antibody titers against HPV31 pseu-
ovirus. Similarly, for animals R39 and R40 only competition with
PV33 or HPV58 VLP reduced the HPV33 neutralizing antibody
iter. These data corroborate the source of the cross-neutralizing
ntibodies, as expected (Fig. 2), and appear to discount any poten-
ial additive effect within the context of a tetravalent immunogen.
n addition, competition for HPV31 and HPV33 neutralizing anti-
odies with HPV31 and HPV33 VLP, respectively, did not impact on
he pseudovirus neutralization of the archetypal HPV16 and HPV58
seudoviruses, respectively.
.  DiscussionWe  undertook a comprehensive evaluation of the antigenic and
mmunogenic properties of the major capsid proteins derived from
PV genotypes within the Alpha-7 and Alpha-9 species groups.pha-7 and Alpha-9 pseudoviruses by serum from NZW rabbits immunized with
unization with three doses of indicated VLP and tested against indicated Alpha-7,
We immunized BALB/c mice and NZW rabbits with Cervarix®
and compared the resulting HPV16, HPV31 and BPV neutralization
titers to those generated in humans [20]. The virtual absence of
HPV31 cross-neutralizing antibodies in mice sera, compared to the
similar HPV31 neutralizing antibody titers generated in rabbits and
humans, led us to select NZW rabbits as the host species for the
remainder of the study.
The  neutralization checkerboard derived using single VLP
immunogens and pseudovirus target antigens corroborates and
extends previous observations on the largely type-speciﬁc
nature of VLP-derived neutralizing antibodies. However, we
did observe reciprocal cross-neutralization between HPV33
and HPV58 and, to a lesser extent, between HPV39 and
HPV59 suggesting some antigenic similarity between these
genotypes. A genetic distance matrix of the amino acid
sequences of the surface-exposed loops further clariﬁed the
relationships between these Alpha-7 and Alpha-9 genotypes
[39–41] and suggested that the observed antigenic proximity
of HPV33 and HPV58 may  be reﬂected in the L1 amino acid
sequence similarity of these two types, although the appar-
ent reciprocal recognition between HPV39 and HPV59 is less
6552 S.L. Bissett et al. / Vaccine 32 (2014) 6548–6555
Fig. 3. Phylogenetic relationship between the major capsid proteins of the Alpha-7 and Alpha-9 genotypes. (A) Amino acid sequences of the L1 major capsid proteins
representing both VLP and pseudoviruses of the Alpha-7 (HPV18, HPV39, HPV45, HPV59, HPV68) and Alpha-9 (HPV16, HPV31, HPV33, HPV35, HPV52, HPV58) genotypes
and the control BPV [20]. Radial representation of NJ tree with branches having less than 80% bootstrap (n = 500 replicates) support (HPV35 and HPV59) indicated in gray. (B)
Heatmap  representation of inter-genotype genetic distances based upon external surface loops only or remaining (non-loop) backbone for the L1 proteins of the indicated
Alpha-7 and Alpha-9 genotypes. Key indicates heatmap gradient.
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Immunog en Rabbi t 16 31 33 35 52 58 18 39 45 59 68 Log10
R37  Pre 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
R38  Pre 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 2.0
R39  Pre 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 3.0
R40  Pre 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 4.0
R41  Pre 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 5.0
R37 Post 5.5 1.4 2.9 1.9 1.4 4.9 4.9 4.8 1.5 1.6 1.6 1.0 6.0
R38  Post 4.9 2.3 1.9 1.0 1.3 4.9 4.2 4.3 1.0 1.0 1.0 1.0
R39  Post 5.1 2.4 3.4 1.7 2.1 5.0 4.2 4.7 1.6 1.3 1.4 1.0
R40 Post 5.4 1.9 3.4 1.4 2.1 5.1 4.1 4.6 1.0 1.0 1.6 1.0
R41  Post 5.2 1.0 4.2 2.1 1.0 5.1 5.2 4.7 1.5 1.9 1.8 1.0
Tetravalent 
VLP16 VLP18 
VLP39 VLP58
Alph a-9 Alph a-7
Pseudo virus
BPV
Fig. 4. Heatmap of type-speciﬁc and cross-neutralizing antibody responses against Al
tetravalent VLP. Log10 neutralization titers of sera against indicated Alpha-7, Alpha-9 or B
immunization with three doses of tetravalent VLP formulation. Key indicates log10 heatm
Table 1
Speciﬁcity of rabbit neutralizing antibodies elicited to tetravalent immunogen.a
Rabbit Competing
antigen
Fold  reduction in neutralizing titer to indicated
pseudovirus (PSV) by addition of VLP
compared to no VLP controlb
PSV16 PSV31 PSV33 PSV58
R38
VLP16  169 19 ≤1 ≤1
VLP31 ≤1 19 ≤1 ≤1
VLP33 ≤1 ≤1 ≤1 ≤1
VLP58 ≤1 ≤1 ≤1 455
R39
VLP16 1052 26 ≤1 ≤1
VLP31 ≤1 10 ≤1 ≤1
VLP33 ≤1 ≤1 39  ≤1
VLP58 ≤1 ≤1 76 579
R40
VLP16 304 ≤1 ≤1 ≤1
VLP31 ≤1 2 ≤1 ≤1
VLP33 ≤1 ≤1 17 ≤1
VLP58 ≤1 ≤1 96 398
a Tetravalent immunogen comprised VLP derived from HPV16, HPV18, HPV39 and
HPV58.
b Fold reduction in neutralizing titer of indicated serum (R38, R39 or R40) against
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bvious from the phylogenetic relationship between these two
ypes.
A shortcoming to this study was that we  did not observe
onsistent cross-neutralization of HPV31 and HPV45 following
mmunization with individual VLP representing HPV16 and HPV18,
espectively, as expected [10,17–20]. This contrasts with the gener-
tion of HPV31 antibodies in NZW rabbits following immunization
ith Cervarix® and immunization with the tetravalent preparation
hat generated a broad response, including cross-neutralization of
PV31 and HPV45 pseudoviruses. There are possible reasons for
hese discrepancies, including potential differences in the exact
LP and adjuvant formulations between the individual and tetrava-
ent preparations, the potential sub-optimal immunostimulatory
apacity of commercial adjuvants and in house formulation, the
ariability inherent in using small groups of animals and the pos-
ibility of differential immunogenicity when certain VLP are used
n combination, not apparent when used individually. The type-
peciﬁc neutralization titers against HPV16, HPV18, HPV39 and
PV58 were similar in the individual and tetravalent preparations,
uggesting that any formulation differences were quite subtle.
hese data also suggest that the type-speciﬁc responses did not suf-
er from immune interference, as has been reported from the use of
ther multivalent preparations containing HPV58 VLP [42]. We  didpha-7 and Alpha-9 pseudoviruses by serum from NZW rabbits immunized with
PV pseudoviruses taken from NZW rabbits (n = 5) prior to (Pre) and following (Post)
ap gradient.
not test other multivalent formulations using other combinations
of antigens which may  have been informative.
Few MAbs have been generated against VLP from genotypes
other than HPV6, HPV11, HPV16 and HPV18 [40,43,44], therefore
data on the antigenicity of the L1 protein is largely limited to these
genotypes. MAbs capable of binding L1 proteins representing mul-
tiple genotypes from the same species group can be found [40,44].
However, apart from cross-neutralization between HPV18 and
HPV45 which appears to be replicated by available MAbs [17,40],
no other inter-genotype cross-neutralizing MAbs have been iden-
tiﬁed. Little is known about the speciﬁcity of antibodies elicited
by the current HPV vaccines except that cross-reactive antibodies
are derived from the immunizing HPV16 and HPV18 VLP [45], as
expected, and that cross-neutralizing antibodies against genotypes
in the Alpha-9 species group appear to be a minority population
[33]. In the present study, competition of HPV31 and HPV33 neu-
tralizing antibodies by addition of homologous VLP and the lack of
an impact on the archetypal HPV16 and HPV58 pseudovirus neu-
tralization titers, respectively, appear to corroborate observations
[33] that cross-neutralizing antibodies comprise minor speciﬁcities
within the antibody repertoire elicited following VLP immuniza-
tion. However, differential afﬁnities for the immunizing and target
antigens cannot be ruled out by this approach.
Cross-neutralizing antibody titers generated by HPV33 or
HPV58 in the individual preparations (or by HPV58 in the
tetravalent preparation) were an order of magnitude higher than
those elicited by HPV16 VLP against HPV31 pseudovirus in the
tetravalent preparation. If cross-neutralizing antibodies against
HPV31 detected in the serum and genital secretions of vaccinees
[10,18–20] are involved in mediating cross-protection [1,15,16]
then one could postulate that the higher levels of cross-neutralizing
antibodies elicited by immunization with HPV33 (or HPV58) would
be at least equally protective. A similar judgment could be leveled at
HPV39 VLP which generated neutralizing antibodies against HPV59
and HPV68. These data suggest that a multivalent next generation
vaccine could perhaps be optimized to generate antibodies capable
of recognizing a wide array of Alpha-7 and Alpha-9 HPV genotypes
with a limited number of L1 VLP immunogens.
Alternatively, these data could also be used to support the
approach of a multivalent next generation vaccine that wholly
relies on the generation of high titer type-speciﬁc antibodies. A next
generation HPV vaccine comprising multiple VLP, such as the V503
vaccine candidate [24], is likely to provide greater coverage than thecines [46]. Two other next generation VLP-based vaccine candidates
may also be in the pipeline: one containing HPV16, HPV18, HPV31
and HPV45 VLP and another comprising HPV16, HPV18, HPV33 and
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PV58 VLP [47]. There are signiﬁcant cost implications for such
accines though these may  be mitigated by observations that type-
peciﬁc antibody titers following reduced dosing schedules of the
urrent HPV vaccines were non-inferior to those generated under
he standard three dose schedule [25–27]. Fewer than three vaccine
oses, however, may  impact on the generation of cross-neutralizing
ntibodies [10,25] due to their reduced kinetics and the low levels
ound in the serum and genital secretions of vaccinees compared
o vaccine type antibodies [10,18,19,33,48]. Given the low and pos-
ibly transient levels of cross-neutralizing antibodies generated by
mmunization with VLP, a single dose of a multivalent vaccine may
e sufﬁcient to elicit appropriate high titer, type-speciﬁc antibodies
gainst a range of incorporated genotypes.
In summary, these data clarify the extent of antigenic diversity of
he major capsid proteins of HPV genotypes that segregate into the
lpha-7 and Alpha-9 species groups, have implications for the opti-
ized composition of next generation HPV vaccines based upon L1
LP and contribute to our understanding of the immunogenicity of
he major capsid protein of HPV.
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